(NPR) Johnson & Johnson Vaccine Is 66% Effective In Preventing Moderate To Severe COVID-19

Johnson & Johnson Vaccine Is 66% Effective In Preventing Moderate To Severe COVID-19

Pharmacy technician Sara Berech prepared a dose of the Johnson & Johnson COVID-19 vaccine in December for a clinical trial that includes Rocky Mountain Regional VA Medical Center in Aurora, Colo.



Michael Ciaglo/Getty Images


hide caption

toggle caption

Michael Ciaglo/Getty Images

Coronavirus Updates

Johnson & Johnson Vaccine Is 66% Effective In Preventing Moderate To Severe COVID-19

The vaccine did better at preventing disease in this country – 72% percent — and less well in South Africa – 57% efficacy. The efficacy seen in Latin America was 66%.